Subfatin and asprosin, two new metabolic players of polycystic ovary syndrome

References

• Alan M, Gurlek B, Yilmaz A, Aksit M, Aslanipour B, Gulhan I, et al. 2019. Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome. Gynecological Endocrinology 35:220–223.
   PubMed Web of Science ®Google Scholar
• AlKhairi I, Cherian P, Abu-Farha M, Madhoun AA, Nizam R, Melhem M, et al. 2019. Increased expression of meteorin-like hormone in type 2 diabetes and obesity and its association with irisin. Cells 8:E1283.
   PubMed Web of Science ®Google Scholar
• Bani Mohammad M, Majdi Seghinsara A. 2017. Polycystic ovary syndrome (PCOS), diagnostic criteria, and AMH. Asian Pacific Journal of Cancer Prevention: APJCP 18:17–21.
   PubMedGoogle Scholar
• Bickerton AS, Clark N, Meeking D, Shaw KM, Crook M, Lumb P, et al. 2005. Cardiovascular risk in women with polycystic ovarian syndrome (PCOS). Journal of Clinical Pathology 58:151–154.
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z. 2019. The possible practical implication of high CRP levels in PCOS. Clinical Medicine Insights. Reproductive Health 13:1179558119861936.
   Web of Science ®Google Scholar
• Bothou A, Koutlaki N, Iatrakis G, Mastorakos G, Tsikouras P, Liberis V, et al. 2017. Antimüllerian hormone as indicator of ovarian dysfunction. Acta Endocrinologica (Bucharest) 13:237–245.
   PubMed Web of Science ®Google Scholar
• Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O, et al. 2004. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. The Journal of Clinical Endocrinology & Metabolism 89:2160–2165.
   PubMed Web of Science ®Google Scholar
• Broekmans FJ, Knauff EA, Valkenburg O, Laven JS, Eijkemans MJ, Fauser BC. 2006. PCOS according to the Rotterdam consensus criteria: Change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG: An International Journal of Obstetrics and Gynaecology 113:1210–1217.
   PubMed Web of Science ®Google Scholar
• Carmina E. 2004. Diagnosis of polycystic ovary syndrome: from NIH criteria to ESHRE-ASRM guidelines. Minerva Ginecologica 56:1–6.
   PubMedGoogle Scholar
• Chang CL, Huang SY, Hsu YC, Chin TH, Soong YK. 2019. The serum level of irisin, but not asprosin, is abnormal in polycystic ovary syndrome patients. Scientific Reports 9:6447.
   PubMed Web of Science ®Google Scholar
• Coelho M, Oliveira T, Fernandes R. 2013. Biochemistry of adipose tissue: an endocrine organ. Archives of Medical Science 9:191–200.
   PubMed Web of Science ®Google Scholar
• Dadmanesh M, Aghajani H, Fadaei R, Ghorban K. 2018. Lower serum levels of meteorin-like/subfatin in patients with coronary artery disease and type 2 diabetes mellitus are negatively associated with insulin resistance and inflammatory cytokines. PLoS One 13:e0204180.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Dunaif A. 2012. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocrine Reviews 33:981–1030.
   PubMed Web of Science ®Google Scholar
• Duerrschmid C, He Y, Wang C, Li C, Bournat JC, Romere C, et al. 2017. Asprosin is a centrally acting orexigenic hormone. Nature Medicine 23:1444–1453.
   PubMed Web of Science ®Google Scholar
• Ebrahimi-Mamaghani M, Saghafi-Asl M, Pirouzpanah S, Aliasgharzadeh A, Aliashrafi S, Rezayi N, et al. 2015. Association of insulin resistance with lipid profile, metabolic syndrome, and hormonal aberrations in overweight or obese women with polycystic ovary syndrome. Journal of Health. Population and Nutrition 33:157–167.
   PubMed Web of Science ®Google Scholar
• Ferriman D, Gallwey JD. 1961. Clinical assessment of body hair growth in women. The Journal of Clinical Endocrinology and Metabolism 21:1440–1447.
   PubMed Web of Science ®Google Scholar
• Głuszak O, Stopińska-Głuszak U, Glinicki P, Kapuścińska R, Snochowska H, Zgliczyński W, et al. 2012. Phenotype and metabolic disorders in polycystic ovary syndrome. ISRN Endocrinology 2012:569862.
   PubMedGoogle Scholar
• González F. 2012. Inflammation in Polycystic Ovary Syndrome: underpinning of insulin resistance and ovarian dysfunction. Steroids 77:300–305.
   PubMed Web of Science ®Google Scholar
• Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. 2001. Low grade chronic inflammation in women with polycystic ovarian syndrome. The Journal of Clinical Endocrinology and Metabolism 86:2453–2455.
   PubMed Web of Science ®Google Scholar
• Kuliczkowska-Płaksej J, Mierzwicka A, Jończyk M, Stachowska B, Urbanovych A, Bolanowski M. 2019. Adropin in women with polycystic ovary syndrome. Endokrynologia Polska 70:151–156.
   PubMed Web of Science ®Google Scholar
• Lee JH, Kang YE, Kim JM, Choung S, Joung KH, Kim HJ, et al. 2018. Serum meteorin-like protein levels decreased in patients newly diagnosed with type 2 diabetes. Diabetes Res. Clin. Pract 135:7–10.
   PubMed Web of Science ®Google Scholar
• Li X, Liao M, Shen R, Zhang L, Hu H, Wu J, et al. 2018. Plasma asprosin levels are associated with glucose metabolism, lipid, and sex hormone profiles in females with metabolic-related diseases. Mediators of Inflammation 2018:7375294.
   PubMed Web of Science ®Google Scholar
• Li ZY, Song J, Zheng SL, Fan MB, Guan YF, Qu Y, et al. 2015. Adipocyte Metrnl antagonizes insulin resistance through PPARγ signaling. Diabetes 64:4011–4022.
   PubMed Web of Science ®Google Scholar
• Li ZY, Zheng SL, Wang P, Xu TY, Guan YF, Zhang YJ, et al. 2014. Subfatin is a novel adipokine and unlike meteorin in adipose and brain expression. CNS Neuroscience and Therapeutics 20:344–354.
   PubMed Web of Science ®Google Scholar
• Liu Q, Xie YJ, Qu LH, Zhang MX, Mo ZC. 2019. Dyslipidemia involvement in the development of polycystic ovary syndrome. Taiwanese Journal of Obstetrics and Gynecology 58:447–453.
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419.
   PubMed Web of Science ®Google Scholar
• Nishino J, Yamashita K, Hashiguchi H, Fujii H, Shimazaki T, Hamada H. 2004. Meteorin: a secreted protein that regulates glial cell differentiation and promotes axonal extension. The EMBO Journal 23:1998–2008.
   PubMed Web of Science ®Google Scholar
• Pellitero S, Piquer-Garcia I, Ferrer-Curriu G, Puig R, Martínez E, Moreno P, et al. 2018. Opposite changes in meteorin-like and oncostatin m levels are associated with metabolic improvements after bariatric surgery. International Journal of Obesity (2005) 42:919–922.
   PubMed Web of Science ®Google Scholar
• Polak K, Czyzyk A, Simoncini T, Meczekalski B. 2017. New markers of insulin resistance in polycystic ovary syndrome. Journal of Endocrinological Investigation 40:1–8.
   PubMed Web of Science ®Google Scholar
• Rojas J, Chávez M, Olivar L, Rojas M, Morillo J, Mejías J, et al. 2014. Polycystic ovary syndrome, insulin resistance, and obesity: navigating the pathophysiologic labyrinth. International Journal of Reproductive Medicine 2014:719050.
   PubMedGoogle Scholar
• Romere C, Duerrschmid C, Bournat J, Constable P, Jain M, Xia F, et al. 2016. Asprosin, a fasting-induced glucogenic protein hormone. Cell 165:566–579.
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. 2004. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility 81:19–25.
   Web of Science ®Google Scholar
• Sonne DP, Hemmingsen B. 2017. Comment on American Diabetes Association. Standards of medical care in diabetes-2017. Diabetes Care 40: e92–S135.
   PubMed Web of Science ®Google Scholar
• Stein IF, Leventhal ML. 1935. Amenorrhea associated with bilateral polycystic ovaries. American Journal of Obstetrics and Gynecology 29:181–191.
   Google Scholar
• Wang K, Li F, Wang C, Deng Y, Cao Z, Cui Y, et al. 2019. Serum levels of meteorin-like (Metrnl) are increased in patients with newly diagnosed type 2 diabetes mellitus and are associated with insulin resistance. Medical Science Monitor 25:2337–2343.
   PubMed Web of Science ®Google Scholar
• Witchel SF, Oberfield SE, Peña AS. 2019. Polycystic ovary syndrome: pathophysiology, presentation, and treatment with emphasis on adolescent girls. Journal of the Endocrine Society 3:1545–1573.
   PubMed Web of Science ®Google Scholar
• Zhang L, Chen C, Zhou N, Fu Y, Cheng X. 2019. Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clinica Chimica Acta 489:183–188.
   PubMed Web of Science ®Google Scholar
• Zheng SL, Li ZY, Song J, Liu JM, Miao CY. 2016. Metrnl: a secreted protein with new emerging functions. Acta Pharmacol Sin 37:571–579.
   PubMed Web of Science ®Google Scholar